NCT02265510 2020-04-17An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated83 enrolled 31 charts
NCT00895687 2015-07-13Study of Erlotinib in Combination With BortezomibM.D. Anderson Cancer CenterPhase 1 Completed24 enrolled